- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05836532
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
Mitral regurgitation is a pathology affecting the left atrioventricular valve that causes a volumetric and pressure overload in the left chambers due to the loss of unidirectionality normally guaranteed by the cardiac valve system. The gold standard for severe mitral regurgitation is currently mitral valve plastic surgery.
Edge to edge, on the other hand, allows shorter CEC and aortic clamping times and does not require significant surgical experience in the field of mitral valve repair, therefore edge to edge could be an excellent strategy in patients suffering from mitral regurgitation caused by P2 prolapse when quadrangular resection cannot be performed.
The main objective of the present study is to examine the medium to long-term outcomes (in terms of survival and plastic outcomes) of patients undergoing central edge-to-edge to treat posterior flap pathology (P2).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20132
- IRCCS Ospedale San Raffaele - Cardiac Surgery Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Mitral regurgitation with degenerative etiology
- Mitral pathology exclusively dependent on P2
- Surgical creation of a double mitral valve orifice with or without a ring as the only mitral valve repair technique.
Exclusion Criteria:
- Other mitral regurgitation etiologies (eg. functional, radiation-induced, rheumatic...)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MR 2+ or more recurrency
Time Frame: through study completion, a minimum of 2 years
|
through study completion, a minimum of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reintervention
Time Frame: through study completion, a minimum of 2 years
|
through study completion, a minimum of 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LORD-P2_DMR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Xiao-dong ZhuangNot yet recruitingMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationChina
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve RegurgitationUnited States
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Sun Yat-sen UniversityRecruitingMitral Insufficiency | Mitral Regurgitation (MR)China
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
Clinical Trials on Central edge-to-edge
-
Beijing Anzhen HospitalNot yet recruitingAtrial Functional Mitral RegurgitationChina
-
Michele De BonisCompletedMitral RegurgitationItaly
-
Robert Bosch Medical CenterRecruitingFrailty | Cardio-Renal Syndrome | Tricuspid Valve Insufficiency | Tricuspid RegurgitationGermany
-
Medical University of WarsawMedical University of Silesia; Poznan University of Medical Sciences; Medical... and other collaboratorsRecruitingHeart Failure | Valve Heart Disease | Tricuspid RegurgitationPoland
-
Deutsches Herzzentrum MuenchenRecruitingMitral Valve Stenosis | Mitral Valve Regurgitation | Tricuspid Valve RegurgitationGermany
-
Abbott Medical DevicesEnrolling by invitationTricuspid Regurgitation (TR)United States, Italy
-
Michele De BonisCompletedDegenerative Mitral Valve DiseaseItaly
-
Barts & The London NHS TrustKing's College Hospital NHS Trust; Royal Brompton & Harefield NHS Foundation... and other collaboratorsNot yet recruiting
-
Istituto Auxologico ItalianoRecruitingTricuspid RegurgitationItaly
-
AZ Sint-Jan AVNot yet recruiting